Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.
Identifieur interne : 001743 ( PubMed/Corpus ); précédent : 001742; suivant : 001744Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.
Auteurs : Yoshikuni Mizuno ; Kazuko Hasegawa ; Tomoyoshi Kondo ; Sadako Kuno ; Mitsutoshi YamamotoSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2010.
English descriptors
- KwdEn :
- Aged, Analysis of Variance, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Parkinson Disease (drug therapy), Purinergic P1 Receptor Antagonists (therapeutic use), Purines (therapeutic use), Retrospective Studies, Severity of Illness Index, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Purinergic P1 Receptor Antagonists, Purines.
- drug therapy : Parkinson Disease.
- Aged, Analysis of Variance, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Treatment Outcome.
Abstract
The objectives of this study were to evaluate the efficacy of istradefylline at an oral dose of 20 mg or 40 mg once daily for 12 weeks in Parkinson's disease (PD) patients with motor complications on levodopa therapy based on the change in the daily OFF time compared with placebo and to assess the safety at these doses. A total of 363 subjects were randomly assigned to receive 20 mg/day istradefylline (n = 119), 40 mg/day istradefylline (n = 125), or placebo (n = 119). The primary outcome variable was the change from baseline at endpoint in daily OFF time based on patients' ON/OFF diaries. At endpoint, the daily OFF time reduced from baseline by 1.31 hours for 20 mg/day istradefylline (P = 0.013 as compared to the placebo), 1.58 hours for 40 mg/day istradefylline (P < 0.001), and 0.66 hours for placebo; istradefylline significantly reduced the daily OFF time compared with placebo. The UPDRS Part III subscale score (ON state) reduced by 5.7 at endpoint in both istradefylline groups and 3.7 in the placebo group (P = 0.006 for 20 mg/day and P = 0.006 for 40 mg/day group as compared with placebo). The most commonly reported drug-related treatment emergent adverse event (TEAE) was dyskinesia, which occurred in 2.5% (3/119) of subjects receiving placebo, 8.5% (10/118) receiving 20 mg/day istradefylline, and 6.4% (8/125) receiving 40 mg/day istradefylline. We conclude that istradefylline at 20 mg and 40 mg once daily is effective in relieving wearing-off fluctuations of PD patients. In addition, istradefylline was well tolerated at both doses.
DOI: 10.1002/mds.23107
PubMed: 20629136
Links to Exploration step
pubmed:20629136Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.</title><author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name><affiliation><nlm:affiliation>Department of Neurology, Research Institute for Diseases of Old Age, Juntendo University School of Medicine, Tokyo, Japan. y_mizuno@juntendo.ac.jp</nlm:affiliation></affiliation></author><author><name sortKey="Hasegawa, Kazuko" sort="Hasegawa, Kazuko" uniqKey="Hasegawa K" first="Kazuko" last="Hasegawa">Kazuko Hasegawa</name></author><author><name sortKey="Kondo, Tomoyoshi" sort="Kondo, Tomoyoshi" uniqKey="Kondo T" first="Tomoyoshi" last="Kondo">Tomoyoshi Kondo</name></author><author><name sortKey="Kuno, Sadako" sort="Kuno, Sadako" uniqKey="Kuno S" first="Sadako" last="Kuno">Sadako Kuno</name></author><author><name sortKey="Yamamoto, Mitsutoshi" sort="Yamamoto, Mitsutoshi" uniqKey="Yamamoto M" first="Mitsutoshi" last="Yamamoto">Mitsutoshi Yamamoto</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="doi">10.1002/mds.23107</idno><idno type="RBID">pubmed:20629136</idno><idno type="pmid">20629136</idno><idno type="wicri:Area/PubMed/Corpus">001743</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.</title><author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name><affiliation><nlm:affiliation>Department of Neurology, Research Institute for Diseases of Old Age, Juntendo University School of Medicine, Tokyo, Japan. y_mizuno@juntendo.ac.jp</nlm:affiliation></affiliation></author><author><name sortKey="Hasegawa, Kazuko" sort="Hasegawa, Kazuko" uniqKey="Hasegawa K" first="Kazuko" last="Hasegawa">Kazuko Hasegawa</name></author><author><name sortKey="Kondo, Tomoyoshi" sort="Kondo, Tomoyoshi" uniqKey="Kondo T" first="Tomoyoshi" last="Kondo">Tomoyoshi Kondo</name></author><author><name sortKey="Kuno, Sadako" sort="Kuno, Sadako" uniqKey="Kuno S" first="Sadako" last="Kuno">Sadako Kuno</name></author><author><name sortKey="Yamamoto, Mitsutoshi" sort="Yamamoto, Mitsutoshi" uniqKey="Yamamoto M" first="Mitsutoshi" last="Yamamoto">Mitsutoshi Yamamoto</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Analysis of Variance</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Purinergic P1 Receptor Antagonists (therapeutic use)</term><term>Purines (therapeutic use)</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Purinergic P1 Receptor Antagonists</term><term>Purines</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Analysis of Variance</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objectives of this study were to evaluate the efficacy of istradefylline at an oral dose of 20 mg or 40 mg once daily for 12 weeks in Parkinson's disease (PD) patients with motor complications on levodopa therapy based on the change in the daily OFF time compared with placebo and to assess the safety at these doses. A total of 363 subjects were randomly assigned to receive 20 mg/day istradefylline (n = 119), 40 mg/day istradefylline (n = 125), or placebo (n = 119). The primary outcome variable was the change from baseline at endpoint in daily OFF time based on patients' ON/OFF diaries. At endpoint, the daily OFF time reduced from baseline by 1.31 hours for 20 mg/day istradefylline (P = 0.013 as compared to the placebo), 1.58 hours for 40 mg/day istradefylline (P < 0.001), and 0.66 hours for placebo; istradefylline significantly reduced the daily OFF time compared with placebo. The UPDRS Part III subscale score (ON state) reduced by 5.7 at endpoint in both istradefylline groups and 3.7 in the placebo group (P = 0.006 for 20 mg/day and P = 0.006 for 40 mg/day group as compared with placebo). The most commonly reported drug-related treatment emergent adverse event (TEAE) was dyskinesia, which occurred in 2.5% (3/119) of subjects receiving placebo, 8.5% (10/118) receiving 20 mg/day istradefylline, and 6.4% (8/125) receiving 40 mg/day istradefylline. We conclude that istradefylline at 20 mg and 40 mg once daily is effective in relieving wearing-off fluctuations of PD patients. In addition, istradefylline was well tolerated at both doses.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20629136</PMID><DateCreated><Year>2010</Year><Month>08</Month><Day>02</Day></DateCreated><DateCompleted><Year>2010</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Jul</Month><Day>30</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.</ArticleTitle><Pagination><MedlinePgn>1437-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.23107</ELocationID><Abstract><AbstractText>The objectives of this study were to evaluate the efficacy of istradefylline at an oral dose of 20 mg or 40 mg once daily for 12 weeks in Parkinson's disease (PD) patients with motor complications on levodopa therapy based on the change in the daily OFF time compared with placebo and to assess the safety at these doses. A total of 363 subjects were randomly assigned to receive 20 mg/day istradefylline (n = 119), 40 mg/day istradefylline (n = 125), or placebo (n = 119). The primary outcome variable was the change from baseline at endpoint in daily OFF time based on patients' ON/OFF diaries. At endpoint, the daily OFF time reduced from baseline by 1.31 hours for 20 mg/day istradefylline (P = 0.013 as compared to the placebo), 1.58 hours for 40 mg/day istradefylline (P < 0.001), and 0.66 hours for placebo; istradefylline significantly reduced the daily OFF time compared with placebo. The UPDRS Part III subscale score (ON state) reduced by 5.7 at endpoint in both istradefylline groups and 3.7 in the placebo group (P = 0.006 for 20 mg/day and P = 0.006 for 40 mg/day group as compared with placebo). The most commonly reported drug-related treatment emergent adverse event (TEAE) was dyskinesia, which occurred in 2.5% (3/119) of subjects receiving placebo, 8.5% (10/118) receiving 20 mg/day istradefylline, and 6.4% (8/125) receiving 40 mg/day istradefylline. We conclude that istradefylline at 20 mg and 40 mg once daily is effective in relieving wearing-off fluctuations of PD patients. In addition, istradefylline was well tolerated at both doses.</AbstractText><CopyrightInformation>(c) 2010 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mizuno</LastName><ForeName>Yoshikuni</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Research Institute for Diseases of Old Age, Juntendo University School of Medicine, Tokyo, Japan. y_mizuno@juntendo.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Kazuko</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kondo</LastName><ForeName>Tomoyoshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kuno</LastName><ForeName>Sadako</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Mitsutoshi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>Japanese Istradefylline Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058915">Purinergic P1 Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2GZ0LIK7T4</RegistryNumber><NameOfSubstance UI="C111599">istradefylline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D058915">Purinergic P1 Receptor Antagonists</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011687">Purines</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Sakou</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shoji</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abe</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nomura</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maeda</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shintani</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tamaoka</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirata</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hishida</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakano</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okamoto</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asahina</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shimura</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hashida</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mochizuki</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mizusawa</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanajima</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakamura</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yokochi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yokochi</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuno</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takahashi</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morita</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miyajima</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ohashi</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atsumi</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mizoguchi</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hattori</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sawada</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tatsuoka</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fujimura</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miwa</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakashima</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoshinaga</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nomoto</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamada</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uozumi</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kondo</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanji</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takeda</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawashima</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ishigaki</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23107</ArticleId><ArticleId IdType="pubmed">20629136</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001743 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001743 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:20629136
|texte= Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:20629136" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |